<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360671</url>
  </required_header>
  <id_info>
    <org_study_id>A1481294</org_study_id>
    <secondary_id>PPHN MIRROR STUDY</secondary_id>
    <nct_id>NCT01360671</nct_id>
  </id_info>
  <brief_title>IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn</brief_title>
  <official_title>An Open Label Single Arm, Single Centre Study to Investigate the Safety and Efficacy of IV Sildenafil in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of iv sildenafil in term and near term infants with PPHN
      (persistent pulmonary hypertension of the newborn), by measuring the need for inhaled nitric
      oxide (iNO) or extracorporeal membrane oxygenation (ECMO) compared to a historical control
      group not treated with sildenafil.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - incidence of treatment failure</measure>
    <time_frame>Day 1-14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for inhaled nitric oxide or Extracorporeal membrane oxygenation</measure>
    <time_frame>Day 1-14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in oxygenation index</measure>
    <time_frame>6 &amp; 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in differential saturation</measure>
    <time_frame>6 &amp; 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Days 1-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initiation of sildenafil to inhaled nitric oxide or extracorporeal membrane oxygenation</measure>
    <time_frame>Days 1-14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Persistent Pulmonary Hypertension of the Newborn</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iv sildenafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days</description>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Babies &lt; 72 hours old and at least 34 gestational weeks with PPHN or hypoxic
             respiratory failure associated with idiopathic PPHN, meconium aspiration, sepsis or
             pneumonia

          -  Oxygenation index &gt;15 and &lt; 60

        Exclusion Criteria:

          -  Congenital anomaly

          -  Large left to right intracardiac or ductal shunt

          -  Already on inhaled nitric oxide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481294&amp;StudyName=IV%20Sildenafil%20Persistent%20Pulmonary%20Hypertension%20Of%20The%20Newborn</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>May 24, 2012</last_update_submitted>
  <last_update_submitted_qc>May 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPHN</keyword>
  <keyword>persistent pulmonary hypertension of the newborn</keyword>
  <keyword>sildenafil</keyword>
  <keyword>iv</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

